Comparison of daratumumab-based regimens as second-line therapy in relapsed/ refractory multiple myeloma

被引：0
|
作者：
Charalampous, Charalampos
Goel, Utkarsh
Kapoor, Prashant
Binder, Moritz
Buadi, Francis
Dingli, David
Dispenzieri, Angela
Fonder, Amie L.
Gertz, Morie A.
Gonsalves, Wilson I.
Hayman, Suzanne R.
Hobbs, Miriam A.
Hwa, Yi Lisa
Kourelis, Taxiarchis
Lacy, Martha
Leung, Nelson
Lin, Yi
Warsame, Rahma M.
Rajkumar, S. Vincent
Kumar, Shaji
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20032
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis K.
    Cook, Joselle
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie L.
    Gertz, Morie A.
    Gonsalves, Wilson
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi L.
    Kourelis, Taxiarchis
    Lacy, Martha Q.
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    Charalampos Charalampous
    Utkarsh Goel
    Prashant Kapoor
    Moritz Binder
    Francis K. Buadi
    Joselle Cook
    David Dingli
    Angela Dispenzieri
    Amie L. Fonder
    Morie A. Gertz
    Wilson Gonsalves
    Suzanne R. Hayman
    Miriam A. Hobbs
    Yi L. Hwa
    Taxiarchis Kourelis
    Martha Q. Lacy
    Nelson Leung
    Yi Lin
    Rahma Warsame
    Robert A. Kyle
    S. Vincent Rajkumar
    Shaji K. Kumar
    Blood Cancer Journal, 13
  • [3] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory MM
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Cook, Joselle
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie
    Gertz, Morie
    Gonsalves, Wilson
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert
    Rajkumar, Vincent
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S191 - S191
  • [4] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Tungesvik, Alexandre
    Huang, Jessica
    Sudalagunta, Praneeth
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebeccah
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth
    Brayer, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
  • [5] Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma
    Wang, Jiasheng
    Arroyo-Suarez, Raul
    Tse, William
    BLOOD, 2021, 138 : 3806 - +
  • [6] Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Genuardi, Elisa
    Papadimitriou, Marios
    Diamond, Benjamin
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bolli, Niccolo
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [7] EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
    Dimopoulos, M. A.
    Weisel, K.
    Kaufman, J.
    Sonneveld, P.
    Rizzo, M.
    Xu, Y.
    Fahrbach, K.
    Gaudig, M.
    Slavcev, M.
    Dearden, L.
    Lam, A.
    HAEMATOLOGICA, 2017, 102 : 525 - 526
  • [8] THALIDOMIDE OR BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE AS SECOND-LINE THERAPY FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA: A COMPARISON OF EFFICACY AND TOXICITY
    Varettoni, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 385 - 385
  • [9] Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
    Zhang, Tian-tian
    Wang, Sen
    Wan, Ning
    Zhang, Li
    Zhang, Zugui
    Jiang, Jie
    CLINICAL THERAPEUTICS, 2018, 40 (07) : 1122 - 1139
  • [10] Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma
    Hari, P.
    Romanus, D.
    Henk, H. J.
    Becker, L. K.
    Noga, S. J.
    Morrison, V. A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (01) : 45 - 51
12345